• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Pacira BioSciences Inc.

    11/17/25 10:25:52 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCRX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001875723
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Pacira BioSciences, Inc.
    SEC File Number
    001-35060
    Address of Issuer
    2000 SIERRA POINT PARKWAY
    SUITE 900
    BRISBANE
    CALIFORNIA
    94005
    Phone
    650-242-8052
    Name of Person for Whose Account the Securities are To Be Sold
    SLONIN JONATHAN
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    396095396.404302127511/17/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/30/2021ESPP PurchaseIssuerCheckbox not checked21006/30/2021Cash
    Common07/01/2021Restricted Stock VestingIssuerCheckbox not checked375007/01/2021Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    11/17/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    08/12/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jonathan Slonin

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $PCRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PCRX

    DatePrice TargetRatingAnalyst
    11/17/2025Buy
    H.C. Wainwright
    7/25/2025$30.00Hold → Buy
    Truist
    1/30/2025$8.00 → $25.00Sell → Hold
    Truist
    8/13/2024$30.00 → $8.00Buy → Sell
    Truist
    8/12/2024$42.00 → $11.00Overweight → Neutral
    Piper Sandler
    8/12/2024$45.00 → $10.00Overweight → Underweight
    JP Morgan
    8/12/2024Outperform → Mkt Perform
    Raymond James
    8/12/2024$37.00 → $14.00Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $PCRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

    BRISBANE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 18th at 1:30PM GMT (8:30AM ET).37th Annual Piper Sandler Healthcare Conference on Tuesday, December 2nd at 1:30PM ET. Live audio of the events can be accessed by visiting the "Events" page of the company's website at investor.pacira.com. A replay of the webcasts will also be available for two weeks fol

    11/11/25 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business

    DOMA Controls 6.8% of Pacira Common Stock MIAMI, Nov. 10, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of Pacira BioSciences, Inc. (NASDAQ: PCRX) ("Pacira"), today sent a letter to the Board of Directors of Pacira (the "Board") urging the Board to hire bankers and conduct a full sale process of the company.  The letter can be downloaded here. The full text of the letter follows: November 10th, 2025 To the Board of Directors of Pacira: As you are aware, DOMA Perpetual has amended the 13D, stating our position regarding Pacira. Our ownership stake is now 6.8%.i We have also updated our intentions regarding our ownership. We continue to evaluate the pos

    11/10/25 8:09:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

    -- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the third quarter of 2025. Third Quarter 2025 Financial Highlights Total revenues of $179.5 millionNet product sales of $139.9 million for EXPAREL; $29.0 million for ZILRETTA; and $6.5 million for iovera°Net income of $5.4 million, or $0.12 per sha

    11/6/25 4:01:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Slonin Jonathan sold $95,396 worth of shares (3,960 units at $24.09), decreasing direct ownership by 2% to 178,367 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    11/19/25 4:32:02 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Cross Shawn sold $266,405 worth of shares (12,060 units at $22.09), decreasing direct ownership by 18% to 56,250 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    11/13/25 4:13:23 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Cross Shawn covered exercise/tax liability with 6,690 shares, decreasing direct ownership by 9% to 68,310 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    11/3/25 5:41:34 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bigal Marcelo bought $20,034 worth of shares (1,512 units at $13.25), increasing direct ownership by 18% to 10,142 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    8/19/24 8:25:55 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Brege Laura bought $12,810 worth of shares (1,000 units at $12.81), increasing direct ownership by 6% to 17,552 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    8/19/24 8:25:46 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Yang Michael J. bought $25,800 worth of shares (2,000 units at $12.90), increasing direct ownership by 38% to 7,230 units (SEC Form 4)

    4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

    8/14/24 4:35:09 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Pacira BioSciences

    H.C. Wainwright initiated coverage of Pacira BioSciences with a rating of Buy

    11/17/25 9:41:22 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences upgraded by Truist with a new price target

    Truist upgraded Pacira BioSciences from Hold to Buy and set a new price target of $30.00

    7/25/25 8:53:01 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences upgraded by Truist with a new price target

    Truist upgraded Pacira BioSciences from Sell to Hold and set a new price target of $25.00 from $8.00 previously

    1/30/25 7:16:40 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    SEC Filings

    View All

    SEC Form 144 filed by Pacira BioSciences Inc.

    144 - Pacira BioSciences, Inc. (0001396814) (Subject)

    11/17/25 10:25:52 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Pacira BioSciences Inc.

    SCHEDULE 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

    11/13/25 2:29:19 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Pacira BioSciences Inc.

    10-Q - Pacira BioSciences, Inc. (0001396814) (Filer)

    11/6/25 4:13:49 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Financials

    Live finance-specific insights

    View All

    Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

    -- Third quarter revenues up 6% driven by EXPAREL volume growth of 9% -- -- Several key milestones advance 5x30 path to growth and value creation -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the third quarter of 2025. Third Quarter 2025 Financial Highlights Total revenues of $179.5 millionNet product sales of $139.9 million for EXPAREL; $29.0 million for ZILRETTA; and $6.5 million for iovera°Net income of $5.4 million, or $0.12 per sha

    11/6/25 4:01:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

    BRISBANE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its third quarter financial results after the close of the U.S. markets on Thursday November 6, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the co

    10/30/25 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira BioSciences Reports Second Quarter 2025 Financial Results

    -- Solid execution across corporate, clinical and commercial initiatives -- -- Several key milestones advance 5x30 path to growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Total revenues of $181.1 millionNet product sales of $142.9 million for EXPAREL, $31.3 million for ZILRETTA, and $5.6 million for iovera°Net loss of $4.8 million, or $0.11 per share (basic and di

    8/5/25 4:00:00 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

    SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

    1/19/24 2:40:54 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

    SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

    2/14/23 1:31:32 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

    SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

    1/23/23 3:52:35 PM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PCRX
    Leadership Updates

    Live Leadership Updates

    View All

    Pacira Announces Updates to Board of Directors

    -- Accomplished Business and Financial Leader, Laura Brege, Appointed Chair -- -- Paul J. Hastings and Andreas Wicki, PhD Retire from Board of Directors -- PARSIPPANY, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that Laura Brege has been appointed Chair of the Board. Former Chair Paul J. Hastings and Andreas Wicki, PhD. have retired from the Board. These changes align with Pacira's ongoing commitment to Board refreshment. With these changes, the Board is composed of nine directors, eight of whom are independent and

    1/30/25 8:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VectorY Strengthens Leadership Team with Appointment of Jim Scibetta as New CEO

    Former CEO, Sander van Deventer to become President of R&D Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package Expansion of corporate footprint into the US (Boston) VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241216441837/en/VectorY strengthens Leadership Team with appointment of Jim Scibetta as new CEO (Photo

    12/16/24 7:00:00 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

    enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

    5/15/24 4:05:00 PM ET
    $ENGN
    $NAMS
    $NKTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations